Muraglitazar
As of the edition of 20 October 2026, Muraglitazar is a small molecule: went quiet in 2006; acts on PPARG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2006
- Kind
- Small molecule
- Registered trials
- 10, 1 stopped early
- Disease areas
- Nutrition and metabolism; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Muraglitazar.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARG | Peroxisome proliferator-activated receptor gamma | P37231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 10 | 9 | 0 | 1 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2002 to now |
| Merck & Co. | Lead sponsor of trials | 2005 to now |